CRSwNP - Kronisk rhinosinusitt med nesepolypper
Artikler
Uncontrolled CRSwNP: Position of Advanced Therapy
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic, type 2 inflammatory disease that often remains uncontrolled despite standard medical and surgical treatment. According to the international EUFOREA definition, uncontrolled CRSwNP is defined by1:
- 1. Patient-reported lack of control
- 2. Clinically relevant symptoms of active disease
RELIBIO: Real-life Evaluation of the Efficacy of Biologicals in Chronic Rhinosinusitis With Nasal Polyposis
Dupilumab's* efficacy and safety in severe CRSwNP was established in the LIBERTY NP SINUS-24 and SINUS-52 randomized, double-blind, placebo-controlled phase 3 trials, and is reflected in the approved SmPC.1,2
As real-world context to this robust RCT evidence, the observational RELIBIO study** provides additional insight into clinical effectiveness, treatment response, and switching patterns among 360 patients with severe CRSwNP treated with dupilumab (n=53), omalizumab (n=65) and mepolizumab (n=242) in routine Belgian clinical practice.3
SINUS-24/SINUS-52 Demonstrated Reduced Need for Surgery and Oral Corticosteroids — Dupilumab Real-World Data Reinforces with 100% Reduction in the First Year of Treatment in Patients with Severe Uncontrolled CRSwNP
This Italian monocentric study (De Corso et al., 2022) evaluated the real-life effectiveness of dupilumab over the first year of treatment of severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) (N=57).2 The results from this real-life observational study reinforces the efficacy of dupilumab demonstrated in the SINUS-24 and SINUS-52 randomized clinical trials and both the study design and results are consistent with the approved SmPC.1,2,3
Chronic Rhinosinusitis with Nasal Polyps: The Interplay of Type 2 Inflammation and Smell Loss
Loss of Smell in CRSwNP
Loss of sense of smell is a common symptom of chronic rhinosinusitis with nasal polyps (CRSwNP), but its impact is often underestimated. Learn how olfactory dysfunction affects patient’s quality of life and explore the underlying mechanisms driving smell loss in CRSwNP.
From SINUS-24/SINUS-52 to Real Life: Clinical Trial Efficacy of Dupilumab in CRSwNP reinforced with DUPIREAL’s two-year real-world data
The results from the DUPIREAL real-world study reinforce the efficacy of dupilumab demonstrated in the SINUS-24 and SINUS-52 randomized clinical trials and are consistent with the approved SmPC.1,2,3,4 DUPIREAL is the largest long-term real-world study (n=926) evaluating the effectiveness of dupilumab, including treatment response, disease control and remission, in severe uncontrolled CRSwNP over 2 years.3,4